Life Sciences

  • December 22, 2025

    Fed. Circ. Urged To Preserve Novartis' Bench Trial Loss

    MSN Pharmaceuticals has pushed back against Novartis' efforts to save its case accusing the generic-drug maker of infringing a patent covering the blockbuster cardiovascular drug Entresto, telling the Federal Circuit that the appeal "reveals no district court error, just Novartis' poor litigation strategy."

  • December 19, 2025

    Colo. IVF Co. Says AI Fertility Co. Owes Nearly $900K

    The maker of an in vitro fertilization incubator system has filed a breach of contract lawsuit in Colorado federal court, claiming an artificial intelligence-based fertility company owes it nearly $900,000 for embryoscope incubator systems it sold to the lab.

  • December 19, 2025

    AstraZeneca Unit Ducks Patent Fraud, Not Sham Suit Claims

    A Massachusetts federal judge spared AstraZeneca unit Alexion on Friday from half of a nonprofit insurer's proposed class action, finding the plaintiff too far removed from anticompetitive patent fraud that allegedly propped up blood disorder treatment Soliris, while preserving accusations that Alexion brought sham infringement allegations against would-be rivals.

  • December 19, 2025

    The Top Patent Damages Of 2025

    The largest patent verdict of the year was Apple's $634 million loss against Masimo, and juries issued eight other nine-figure verdicts in 2025 — many of which were against Samsung.

  • December 19, 2025

    Medical, School Groups Seek Order Halting $100K Visa Fee

    A medical practice in rural North Carolina and other employers asked a federal judge Friday to block enforcement of the Trump administration's $100,000 fee on H-1B visas, arguing the "massive" fee hike will inflict irreparable harm on their communities.

  • December 19, 2025

    BigLaw And Boutiques Both Shine In 2025's Top 10 Deals

    A tight circle of elite law firms guided the way as megadeals roared back with force in 2025, while a small group of specialist and international firms also made their mark across global transactions spanning infrastructure, gaming, pharmaceuticals, artificial intelligence and energy.

  • December 19, 2025

    Taxation With Representation: Baker Botts, Morgan Lewis

    In this week's Taxation With Representation, Trump Media and Technology Group merges with fusion power company TAE Technologies, pharmaceutical company Cencora boosts its stake in cancer care company OneOncology, and Phoenix Financial partners with private equity giant Blackstone to plug billions into various credit strategies.

  • December 19, 2025

    J&J, ChemImage Reach Deal After $77M AI Patent Judgment

    Johnson & Johnson has entered an agreement to resolve a lawsuit that ChemImage Corp. had brought alleging the pharmaceutical giant unilaterally ended a deal to develop in-surgery artificial intelligence imaging techniques, after a New York federal judge determined J&J owed $76.6 million in the dispute.

  • December 19, 2025

    AbCellera Gets $36M In Cell Research Patent Settlement

    Canadian biotechnology firm AbCellera said it had reached a $36 million settlement with Bruker Corp. to resolve patent infringement claims related to a cell analysis system.

  • December 19, 2025

    Trump Admin Appeals Harvard Win In $2B Fund Freeze Case

    The Trump administration will ask the First Circuit to overturn a federal judge's ruling that prevented the government from withholding $2.2 billion in federal grants from Harvard University over concerns about antisemitism on campus.

  • December 19, 2025

    Biomedical Co. Gets Approval For Ch. 11 Auction In January

    Eye disease treatment developer Clearside Biomedical on Friday got permission from a Delaware bankruptcy judge for a January auction of its assets after saying it had resolved objections from shareholders and the U.S. Trustee's Office.

  • December 19, 2025

    BioMarin Inks $4.8B Amicus Buy As Patent Litigation Resolved

    BioMarin Pharmaceutical Inc. has agreed to acquire Amicus Therapeutics for $4.8 billion, in a deal bolstered by Amicus' settlement of patent litigation that secures U.S. exclusivity for its Galafold drug until 2037, the companies said Friday.

  • December 18, 2025

    The Biggest Rulings From A Busy Year At The 1st Circ.

    The nation's smallest federal appellate panel punched above its weight in 2025, grappling with numerous suits against the Trump administration, high-profile criminal appeals, a $34 million legal fee bid and a hotly contested kickback law.

  • December 18, 2025

    ITC Clears Toy Gun Imports, Will Review Smart Rings, Vapes

    The U.S. International Trade Commission has had a busy week in intellectual property, determining a series of toy gun imports don't infringe Spin Master patents licensed to Hasbro, instituting reviews requested by companies including Ouraring, AbbVie and Juul, and receiving several new complaints.

  • December 18, 2025

    Eli Lilly Workers Say Justices Needn't Mull Collective Standard

    Eli Lilly workers on Wednesday pressed the U.S. Supreme Court not to disturb a Seventh Circuit decision establishing a new, more flexible standard for certifying collective actions, arguing that there's no "urgent" need for the high court to weigh in on the dispute.

  • December 18, 2025

    InnovAge Investors Get Final OK For $27M Deal, Atty Fees

    A Colorado federal judge has granted final approval to a $27 million settlement between InnovAge Holding Corp., its underwriters and a class of stockholders accusing the senior healthcare company of making misleading statements in an initial public offering that later caused stock prices to tank after a government audit exposed the alleged falsehoods.

  • December 18, 2025

    Top Trade Secrets Decisions Of 2025

    The Ninth Circuit clarified the rules of engagement in trade secrets disputes with guidance on when confidential information must be precisely detailed during litigation, and jurors delivered a $200 million verdict against Walmart over product freshness technology. Here are Law360's picks for the biggest trade secrets decisions of 2025.

  • December 18, 2025

    Top Product Liability Cases Of 2025

    The Fourth Circuit's decision to unravel an early landmark ruling in litigation over the opioid crisis in a suit brought by West Virginia counties against drug distributors tops Law360's list of product liability cases of the past year, as well as a loss for Tesla in a newsworthy trial over the automaker's Autopilot feature. Here's what other cases garnered attorneys' attention in 2025.

  • December 18, 2025

    UC Researchers Near Reinstating $7B In DOE Grants

    A California federal judge said Thursday she's inclined to grant a preliminary injunction ordering the Trump administration to reinstate $7 billion in Department of Energy grants awarded to researchers, saying they were canceled with form letters similar to those she's previously found to violate the Administrative Procedure Act.

  • December 18, 2025

    SF Must Reinstate Worker Fired For Violating COVID Vax Rule

    A California federal judge ordered San Francisco to reinstate a 311 call center agent who was fired for violating a COVID-19 vaccination mandate after he sought an exemption based on his Muslim faith, ruling Thursday that the plaintiff has made a "prima facie case for religious discrimination."

  • December 18, 2025

    AstraZeneca Can't Block Colo. Law Over Drug Discount Rules

    A Colorado federal judge rejected AstraZeneca's effort to block enforcement of a Colorado law surrounding federal 340B drug pricing that requires manufacturers to sell drugs at discounted prices to certain safety net healthcare facilities, ruling Wednesday the law isn't preempted by 340B drug pricing. 

  • December 18, 2025

    HHS Proposes Hospital Ban On Gender Care For Minors

    The Trump administration moved to block all hospitals that receive federal funding from providing gender-affirming care to minors and issued warning letters to a dozen companies Thursday as part of a sweeping push to halt the care nationwide, even in states with legal protections in place.

  • December 18, 2025

    Agita Over Piglets At Party Got Pharma Exec Axed, Suit Says

    The U.S. arm of a Danish pharmaceutical company pushed out a director after he expressed concerns about using baby pigs for a photo op at the company's anniversary party knowing the animals would be euthanized after, a new federal lawsuit alleges.

  • December 18, 2025

    Trump Orders Loosening Of Federal Restrictions On Marijuana

    President Donald Trump on Thursday announced that his administration would instruct federal agencies to loosen restrictions on cannabis via executive order, a historic acknowledgment from the executive branch that the drug has recognized medical uses.

  • December 17, 2025

    Sterne Kessler Draws Scolding, But No Sanctions Midtrial

    A Delaware federal judge said Wednesday she wasn't happy with the tone used by attorneys defending a radiopharmaceutical company from patent infringement claims and that she does not condone the attorneys' conduct in improperly contacting three inventors named in a patent at issue, but she declined to issue the severe sanction of kicking them off the case.

Expert Analysis

  • Pharma Copay Programs Raise Complex Economic Questions

    Author Photo

    The growing prevalence of copay accumulator and maximizer programs in the pharmaceutical industry is drawing increased scrutiny from patients, advocacy groups, lawmakers and courts, bringing complex questions about how financial responsibility for prescription drug purchases is determined and complicating damages assessments in litigation, say analysts at Analysis Group.

  • State False Claims Acts Can Help Curb Opioid Fund Fraud

    Author Photo

    State versions of the federal False Claims Act can play an important role in policing the misuse of opioid settlement funds, taking a cue from the U.S. Department of Justice’s handling of federal fraud cases involving pandemic relief funds, says Kenneth Levine at Stone & Magnanini.

  • Beaming Up Lessons From William Shatner's Failed Patent Bid

    Author Photo

    In a tale that boldly goes where few celebrity inventors have gone before, William Shatner's unsuccessful attempt to patent a smartphone file organization system offers insights about potential pitfalls to avoid in patent applications, say attorneys at King & Spalding.

  • The Pros And Cons Of Levying Value-Based Fees On Patents

    Author Photo

    The potential for a recurring, value-based maintenance fee on patents, while offering some benefits, raises several complications, including that it would likely exceed the U.S. Patent and Trademark Office's statutory authority and reduce research and development activities in the U.S., says Sandip Patel at Marshall Gerstein.

  • Series

    Writing Musicals Makes Me A Better Lawyer

    Author Photo

    My experiences with writing musicals and practicing law have shown that the building blocks for both endeavors are one and the same, because drama is necessary for the law to exist, says Addison O’Donnell at LOIS Law.

  • Between The Lines Of EPO's Adoption Of Color Drawings

    Author Photo

    The European Patent Office's decision to accept patent drawings in color starting in October may enhance clarity in technical disclosures and streamline the examination process, and could also enable new patent filing strategies for international applicants, say attorneys at Miller Canfield.

  • What Prop 65 Ruling Means For Cosmetics, Personal Care Biz

    Author Photo

    A California federal court's recent decision on Proposition 65 warnings is good news for companies in the cosmetics and personal care space, as it will relieve businesses of the need to apply such warnings to products containing titanium dioxide and likely stop a wave of pending failure-to-warn litigation, say attorneys at Morgan Lewis.

  • Series

    Adapting To Private Practice: From Va. AUSA To Mid-Law

    Author Photo

    Returning to the firm where I began my career after seven years as an assistant U.S. attorney in Virginia has been complex, nuanced and rewarding, and I’ve learned that the pursuit of justice remains the constant, even as the mindset and client change, says Kristin Johnson at Woods Rogers.

  • 2 Fed. Circ. Rulings Underscore Patent Prosecution Pitfalls

    Author Photo

    Two recent patent decisions from the Federal Circuit, overturning significant judgments, serve as reminders that claim modifications and cancellations may have substantive effects on the scope of other claims, and that arguments distinguishing prior art and characterizing claims may also limit claim scope, say attorneys at Morgan Lewis.

  • Rebutting Price Impact In Securities Class Actions

    Author Photo

    Defendants litigating securities cases historically faced long odds in defeating class certification, but that paradigm has recently begun to shift, with recent cases ushering in a more searching analysis of price impact and changing the evidence courts can consider at the class certification stage, say attorneys at Katten.

  • 7 Document Review Concepts New Attorneys Need To Know

    Author Photo

    For new associates joining firms this fall, stepping into the world of e-discovery can feel like learning a new language, but understanding a handful of fundamentals — from coding layouts to metadata — can help attorneys become fluent in document review, says Ann Motl at Bowman and Brooke.

  • Ruling On Labor Peace Law Marks Shift For Cannabis Cos.

    Author Photo

    Currently on appeal to the Ninth Circuit, an Oregon federal court’s novel decision in Casala v. Kotek, invalidating a state law that requires labor peace agreements as a condition of cannabis business licensure, marks the potential for compliance uncertainty for all cannabis employers in states with labor peace mandates, say attorneys at Sheppard Mullin.

  • Fed. Circ. Rulings Refine Patent Claim Construction Standards

    Author Photo

    Four Federal Circuit patent decisions this year clarify several crucial principles governing patent claim construction, including the importance of prosecution history, and the need for error-free, precise language from claims drafters, say attorneys at Taft.

  • How Value-Based Patent Fees May Shape IP Strategies

    Author Photo

    If the U.S. Patent and Trademark Office implements rumored plans to correlate patent fees with patent value, the financial and strategic consequences would largely depend on the specifics of how, when and how often patent values are assessed, say attorneys at Cleary.

  • Agentic AI Puts A New Twist On Attorney Ethics Obligations

    Author Photo

    As lawyers increasingly use autonomous artificial intelligence agents, disciplinary authorities must decide whether attorney responsibility for an AI-caused legal ethics violation is personal or supervisory, and firms must enact strong policies regarding agentic AI use and supervision, says Grace Wynn at HWG.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.